All In MedTech

Device Trial Radar · NCT00277069

Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer

INST: Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer

Last checked: Nov 20, 2026Latest source record: Jan 7, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

33

Actual

Start

May 2000

Primary completion

Mar 2005

Study completion Mar 2006

Sponsor

Lead sponsor
University of New MexicoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 13, 2006

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1\. Determine the response rate with this regimen in an anthracycline and taxane resistant cohort of patients.

Conditions

  • Breast
  • Cancer

Interventions

  • CarboplatinDrug

    Carboplatin given at 300mg/m2 IV over 30 minutes day 1, q 21 days

  • CapecitabineDevice

    Capecitabine is administered at 1500mg/m2 PO qd in 2 divided doses day 1-14 q 21 days

  • VinorelbineDrug

    Vinorelbine: 25mg/m2 IV over 10 minutes day 1, 8 q 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measurable disease: Bidimensionally measurable lesions with clearly defined margins by 1) palpation with both diameters greater than 1 cm, 2) CT, MRI with both diameters greater than the distance between cuts of the imaging study.Time frame: disease progression or unacceptable toxicities

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of New Mexico

    Albuquerque, New Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.